Skip to main content

Table 2 Immune checkpoint inhibitor agent administered by malignancy type

From: Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson

  No. (%)
Checkpoint inhibitor Melanoma
n = 120
Solid tumor
n = 148
Hematologic cancer
n = 59
P
Ipilimumab 81 (68) 44 (30) 13 (22) < 0.001
Nivolumab 7 (6) 62 (42) 31 (53)  
Pembrolizumab 23 (19) 31 (21) 15 (25)  
Combinationa 9 (8) 10 (7) 0 (0)  
Atezolizumab 0 (0) 1 (1) 0 (0)  
  1. aCombination therapy consisted of ipilimumab + nivolumab